169 related articles for article (PubMed ID: 17357565)
1. [Superantigens and toxic shock syndrome. A report of three cases treated with intravenous gammaglobulin].
Vázquez García RE; Hernández Bautista V; Espinosa Padilla S
Rev Alerg Mex; 2006; 53(5):183-8. PubMed ID: 17357565
[TBL] [Abstract][Full Text] [Related]
2. T cell activation and cytokine release in streptococcal toxic shock-like syndrome.
Nadal D; Lauener RP; Braegger CP; Kaufhold A; Simma B; Lütticken R; Seger RA
J Pediatr; 1993 May; 122(5 Pt 1):727-9. PubMed ID: 8496751
[TBL] [Abstract][Full Text] [Related]
3. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation.
Arad G; Levy R; Hillman D; Kaempfer R
Nat Med; 2000 Apr; 6(4):414-21. PubMed ID: 10742148
[TBL] [Abstract][Full Text] [Related]
4. Superantigens and streptococcal toxic shock syndrome.
Proft T; Sriskandan S; Yang L; Fraser JD
Emerg Infect Dis; 2003 Oct; 9(10):1211-8. PubMed ID: 14609454
[TBL] [Abstract][Full Text] [Related]
5. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome.
Darenberg J; Söderquist B; Normark BH; Norrby-Teglund A
Clin Infect Dis; 2004 Mar; 38(6):836-42. PubMed ID: 14999628
[TBL] [Abstract][Full Text] [Related]
6. Streptococcal toxic shock syndrome (STSS). An update: a roundtable presentation.
Holm SE; Köhler W; Kaplan EL; Schlievert PM; Alouf JE; Stevens DL; Kotb M
Adv Exp Med Biol; 1997; 418():193-9. PubMed ID: 9331631
[No Abstract] [Full Text] [Related]
7. Superantigenic activity produced by group A streptococcal isolates is neutralized by plasma from IVIG-treated streptococcal toxic shock syndrome patients.
Norrby-Teglund A; Low DE; McGeer A; Kotb M
Adv Exp Med Biol; 1997; 418():563-6. PubMed ID: 9331714
[No Abstract] [Full Text] [Related]
8. Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses.
Schlievert PM
J Allergy Clin Immunol; 2001 Oct; 108(4 Suppl):S107-10. PubMed ID: 11586276
[TBL] [Abstract][Full Text] [Related]
9. Molecular structure of staphylococcus and streptococcus superantigens.
Schlievert PM; Bohach GA; Ohlendorf DH; Stauffacher CV; Leung DY; Murray DL; Prasad GS; Earhart CA; Jablonski LM; Hoffmann ML; Chi YI
J Clin Immunol; 1995 Nov; 15(6 Suppl):4S-10S. PubMed ID: 8613491
[TBL] [Abstract][Full Text] [Related]
10. Toxic shock syndrome in burns: diagnosis and management.
Young AE; Thornton KL
Arch Dis Child Educ Pract Ed; 2007 Aug; 92(4):ep97-100. PubMed ID: 17644672
[TBL] [Abstract][Full Text] [Related]
11. The bacterial superantigen and superantigen-like proteins.
Fraser JD; Proft T
Immunol Rev; 2008 Oct; 225():226-43. PubMed ID: 18837785
[TBL] [Abstract][Full Text] [Related]
12. Streptococcus pyogenes: Insight into the function of the streptococcal superantigens.
Sriskandan S; Faulkner L; Hopkins P
Int J Biochem Cell Biol; 2007; 39(1):12-9. PubMed ID: 17029999
[TBL] [Abstract][Full Text] [Related]
13. Early diagnosis of staphylococcal toxic shock syndrome by detection of the TSST-1 Vbeta signature in peripheral blood of a 12-year-old boy.
Ferry T; Thomas D; Bouchut JC; Lina G; Vasselon-Raina M; Dauwalder O; Gillet Y; Vandenesch F; Floret D; Etienne J
Pediatr Infect Dis J; 2008 Mar; 27(3):274-7. PubMed ID: 18277923
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review.
Perez CM; Kubak BM; Cryer HG; Salehmugodam S; Vespa P; Farmer D
Am J Med; 1997 Jan; 102(1):111-3. PubMed ID: 9209207
[No Abstract] [Full Text] [Related]
15. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production.
Norrby-Teglund A; Kaul R; Low DE; McGeer A; Newton DW; Andersson J; Andersson U; Kotb M
J Immunol; 1996 Apr; 156(8):3057-64. PubMed ID: 8609429
[TBL] [Abstract][Full Text] [Related]
16. Structure and function of streptococcal and staphylococcal superantigens in septic shock.
Bannan J; Visvanathan K; Zabriskie JB
Infect Dis Clin North Am; 1999 Jun; 13(2):387-96, ix. PubMed ID: 10340173
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin therapy for toxic shock syndrome.
Barry W; Hudgins L; Donta ST; Pesanti EL
JAMA; 1992 Jun; 267(24):3315-6. PubMed ID: 1597914
[TBL] [Abstract][Full Text] [Related]
18. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome.
Abinun M; Cant AJ
Lancet; 1994 Jan; 343(8892):300. PubMed ID: 7905129
[No Abstract] [Full Text] [Related]
19. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome.
Schrage B; Duan G; Yang LP; Fraser JD; Proft T
Clin Infect Dis; 2006 Sep; 43(6):743-6. PubMed ID: 16912949
[TBL] [Abstract][Full Text] [Related]
20. A severe case of neonatal toxic shock syndrome-like exanthematous disease with superantigen-induced high T cell response.
Miki M; Uchiyama T; Kato H; Nishida H; Takahashi N
Pediatr Infect Dis J; 2006 Oct; 25(10):950-2. PubMed ID: 17006297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
